P510: THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

• C. DiNardo,
• K. Pratz,
• P. Panayiotidis,
• X. Wei,
• V. Vorobyev,
• Á. Illés,
• I. Kim,
• V. Ivanov,
• G. Ku,
• C. L. Miller,
• M. Zhang,
• F. Tatsch,
• J. Potluri,
• X. Schmidt,
• C. Recher

Affiliations

C. DiNardo

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

K. Pratz

2 Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States of America

P. Panayiotidis

3 Haematology Clinic and BMT Unit, NKUA, Laiko General Hospital, Athens, Greece

X. Wei

4 The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China

V. Vorobyev

5 Department of Hematology, S. P. Botkin City Clinical Hospital, Moscow, Russia

Á. Illés

6 Department of Hematology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

I. Kim

7 Seoul National University Hospital, Seoul, South Korea

V. Ivanov

8 Almazov National Medical Research Centre, Saint Petersburg, Russia

G. Ku

9 Genentech, South San Francisco

C. L. Miller

10 AbbVie, Inc., North Chicago, United States of America

M. Zhang

10 AbbVie, Inc., North Chicago, United States of America

F. Tatsch

10 AbbVie, Inc., North Chicago, United States of America

J. Potluri

10 AbbVie, Inc., North Chicago, United States of America

X. Schmidt

10 AbbVie, Inc., North Chicago, United States of America

C. Recher

11 Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France